Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1265177 | 1.00 | P2RX7 (0.47) | P2RX7DRD2HTR2ADRD3TRPV1 | |
| SCHEMBL600126 | 0.81 | DRD2 (0.49) | P2RX7DRD2HTR2ADRD3TRPV1 | |
| SCHEMBL600125 | 0.81 | DRD2 (0.49) | P2RX7DRD2HTR2ADRD3TRPV1 | |
| SCHEMBL30990005 | 0.73 | MAPK1 (0.40) | P2RX7 | |
| SCHEMBL23977028 | 0.73 | TRPV1 (0.38) | P2RX7TRPV1CNR1 | |
| SCHEMBL12927177 | 0.72 | ADRA2A (0.47) | P2RX7TRPV1 | |
| SCHEMBL30989929 | 0.71 | P2RX7 (0.42) | P2RX7TRPV1 | |
| SCHEMBL30989933 | 0.71 | P2RX7 (0.42) | P2RX7TRPV1 | |
| SCHEMBL31316920 | 0.71 | EPHX2 (0.44) | P2RX7TRPV1 | |
| SCHEMBL19973950 | 0.71 | DRD4 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326647-A1 | 6-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE AND PURINONE DERIVATIVES AND 6-SUBSTITUTED 2-(IMIDAZOIOÝ4,5- C¨PYRIDINYL)PURINE AND PURINONE DERIVATIVES FOR IMMUNOSUPPRESSION | Wyeth LLC (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7919490-B2 | 6-substituted 2-(benzimidazolyl)purine or purinones and 6-substituted 2-(imidazolo[4,5-c]pyridinyl)purine or purinones; Jak3 tyrosine kinase inhibitors; autoimmune and mast cell-mediated diseases, transplant rejection; antiinflammatory agents | WYETH LLC (US) | 2011-04-05 | — | — | US | disclosed |
| US-7915268-B2 | And 8-substituted 2-(imidazolo[4,5-c]pyridinyl)purines; Janus kinase 3 inhibitors; autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection | WYETH LLC (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915268-B2 | And 8-substituted 2-(imidazolo[4,5-c]pyridinyl)purines; Janus kinase 3 inhibitors; autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection | WYETH LLC (US) | 2011-03-29 | — | — | US | disclosed |
| US-7902187-B2 | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression | WYETH LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902187-B2 | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression | WYETH LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7884109-B2 | immunosuppressants such as 2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4R)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)-7H-purin-8(9H)-one, used for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection | WYETH LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884109-B2 | immunosuppressants such as 2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4R)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)-7H-purin-8(9H)-one, used for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection | WYETH LLC (US) | 2011-02-08 | — | — | US | disclosed |
| WO-2010022358-A1 | 6-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE AND PURINONE DERIVATIVES AND 6-SUBSTITUTED 2-(IMIDAZOIO[4,5- C]PYRIDINYL)PURINE AND PURINONE DERIVATIVES FOR IMMUNOSUPPRESSION | LIGAND PHARMACEUTICALS INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| EP-2099800-A1 | 7-SUBSTITUTED PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | Pharmacopeia, LLC (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008060301-A1 | 7-SUBSTITUTED PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA , LLC (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080119496-A1 | 7-Substituted Purine Derivatives for Immunosuppression | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080085898-A1 | 8-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085898-A1 | 8-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| WO-2008043031-A1 | 6-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE AND PURINONE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008043019-A1 | 8-SUBSTITUTED 2-(BENZIMIDAZOLYL) PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC (US) | 2008-04-10 | — | — | WO | disclosed |
| EP-1874772-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | WYETH LLC | 2007-01-25 | — | — | US | disclosed |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | WYETH LLC | 2007-01-25 | — | — | US | disclosed |
| WO-2006108103-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119496-A1 | 7-Substituted Purine Derivatives for Immunosuppression | P2RX7, P2RX5, P2RY1 | P2RX7 1/4885DRD2 1280/4885HTR2A 309/4885 |
| US-20080085898-A1 | 8-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | TPMT, KIT, ADORA2A | P2RX7 5/4885DRD2 1945/4885HTR2A 491/4885 |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | TPMT, P2RY4, P2RY1 | P2RX7 12/4885DRD2 1611/4885HTR2A 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.